Jascayd (nerandomilast) PDUFA Date (Boehringer Ingelheim)
FDA PDUFA decision date for Jascayd (nerandomilast) is October 9, 2025. Developed by Boehringer Ingelheim. Indication: Idiopathic pulmonary fibrosis (IPF). Current status: Approved.
Indication
Idiopathic pulmonary fibrosis (IPF)
Regulatory details
- Company: Boehringer Ingelheim
- Therapeutic area: Rare Disease / Pulmonology
- Application type: NDA
- Review type: Priority
- PDUFA date: 2025-10-09
- Outcome: Approved